While Compugen Ltd has underperformed by -1.29%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, CGEN fell by -4.56%, with highs and lows ranging from $3.03 to $1.35, whereas the simple moving average jumped by 24.90% in the last 200 days.
On January 13, 2025, Oppenheimer started tracking Compugen Ltd (NASDAQ: CGEN) recommending Outperform. A report published by Jefferies on August 05, 2022, Downgraded its rating to ‘Hold’ for CGEN. JMP Securities also rated CGEN shares as ‘Mkt Outperform’, setting a target price of $18 on the company’s shares in an initiating report dated May 26, 2020. Stifel Initiated an Buy rating on May 13, 2020, and assigned a price target of $19. SVB Leerink initiated its ‘Outperform’ rating for CGEN, as published in its report on May 07, 2020. ROTH Capital’s report from April 22, 2020 suggests a price prediction of $28 for CGEN shares, giving the stock a ‘Buy’ rating. SunTrust also rated the stock as ‘Buy’.
Analysis of Compugen Ltd (CGEN)
One of the most important indicators of Compugen Ltd’s future performance is equity, which can be evaluated using several well-rounded types of analysis and research techniques. The goal here is to ensure that your current return on equity of 2.81% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 4.14, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
For any stock, average volume can also provide valuable insight into volatility, and CGEN is recording 633.19K average volume. On a monthly basis, the volatility of the stock is set at 8.11%, whereas on a weekly basis, it is put at 4.41%, with a gain of 1.77% over the past seven days. Furthermore, long-term investors anticipate a median target price of $4.00, showing growth from the present price of $2.30, which can serve as yet another indication of whether CGEN is worth investing in or should be passed over.
How Do You Analyze Compugen Ltd Shares?
The Biotechnology market is dominated by Compugen Ltd (CGEN) based in the Israel. When comparing Compugen Ltd shares with other companies under Healthcare, the P/E value is an influential factor to note. This is because it represents an indication of the future growth of the company in terms of investors’ expectations. Ultimately, the value of the latter should demonstrate steady, rapid growth, which is an accurate measure of the company’s progress. In addition to the value of 119.79, there is a growth in quarterly earnings of 112.72%.
Along with the fundamentals, it is also important to consider how many employees own shares of the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 5.38%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 14.07% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
CGEN shares are owned by institutional investors to the tune of 14.07% at present.
